NeuroPace posts first-ever positive adjusted EBITDA — commercial milestone for responsive neurostimulation
Summary
NeuroPace posted its first-ever positive adjusted EBITDA quarter in late 2025, validating the unit economics of their RNS (responsive neurostimulation) System for drug-resistant epilepsy. The milestone marks the company's transition from research-stage to commercially self-sustaining operations. NeuroPace's 2026 roadmap focuses on the "Nautilus" project — a next-generation smaller form factor device designed to make RNS cranial surgery less invasive and enable earlier use in the treatment paradigm.
Why it matters
First-ever positive EBITDA for a responsive neurostimulation company is the commercial validation that closed-loop BCI can be a sustainable business. NeuroPace's Nautilus smaller form factor will be critical for moving the therapy earlier in epilepsy treatment — currently restricted to patients who have failed multiple medications, but potentially appropriate for earlier intervention if surgical burden decreases.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial